CMS Open Payments · Program Year 2024
Grifols, S.A.
Grifols, S.A. reported $70,151.75 across General Payments, Research, and Ownership to 19 physicians and teaching hospitals across 20 transactions.
- $70.2K
- All-tracks total
- 20
- Transactions
- 19
- Recipients
- −$31.4K
- General Payments vs PY2023
Grifols, S.A. reported $70,151.75 across all CMS Open Payments tracks (General + Research + Ownership) to 19 physicians and teaching hospitals in Program Year 2024 - ranking #1270 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $42,686.65, averaging $3.7K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer grifols-s-a Grifols, S.A.
$70.2K · #1270/1,925 · 0.0% industry · PY2024
- TOT $70.2K
- RANK #1270
- SHARE 0.0%
- TXN 20
- RCP 19
- CAT 5
- GEN $42.7K
- ΔGEN −$31.4K
- TOP1 23.7%
- PY 2024
Volume peers
Nearest volume peer: Servier Affaires Medicales ($70.3K)
Grifols, S.A. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Grifols, S.A.'s CMS-reported General Payments decreased by $31.4K (−42.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: GRIFOLS, S.A.PY2023: GRIFOLS, S.A.PY2024: Grifols, S.A.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $74,086.65
- PY2024
- $42,686.65
What the Data Shows for Grifols, S.A.
In Program Year 2024, Grifols, S.A. reported $70,151.75 in payments to 19 physicians and teaching hospitals across 20 individual transactions, an average of $3.5K per transaction and $3.7K per recipient. That total places Grifols, S.A. at rank #1270 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
6 transactions worth $16.4K make "Compensation for Services Other Than Consulting" the top general-payment category in the 5-category breakdown below, 38.4% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Grifols, S.A. made 5 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $16.4K, 38.4% of General Payments.
Grifols, S.A. reports 5 general-payment categories - the top three are Compensation for Services Other Than Consulting (38.4%), Consulting Fee (33.7%), and Honoraria (14.7%). The remaining 2 categories make up 13.2% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Grifols, S.A. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $16.4K | 6 | 38.4% |
| Consulting Fee | $14.4K | 4 | 33.7% |
| Honoraria | $6.3K | 2 | 14.7% |
| Travel and Lodging | $5.6K | 6 | 13.0% |
| Food and Beverage | $63.27 | 1 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $33,255.37 (77.9%) of $42,686.65 in this company's General Payments records across 8 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Grifols, S.A.
The five named recipients with the highest reported General Payments from this company
- 1
Mark Harris Yazer
$10,133.39 across 8 reported transactions
- 2
University Of Washington Med Ctr
$9,880.00 across 3 reported transactions
- 3
Jerrold H Levy
$6,574.59 across 2 reported transactions
- 4
James K Stoller
$3,363.73 across 2 reported transactions
- 5
Gregory S Martin
$3,303.66 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Grifols, S.A.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Grifols, S.A..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Grifols, S.A..
Showing 6 of 1,924 companies with CMS-reported payment data.
Biocircuit Technologies Inc
Silony Medical Corp.
Coastal Medical Technologies Llc
Nexus CMF, LLC
Institut de Recherches Internationales Servier
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.